Swasti Rastogi

Ms. Swasti Rastogi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2025 in Cells
Verified
Journal Article
Open access
PDF file
SRSwasti Rastogi
Swasti Rastogi
AGAnna Grimm
Anna Grimm
BBBrooke Biby
Brooke Biby
LMLucila Mathieu
Lucila Mathieu
BTBrian Trinh
Brian Trinh
KNKenia Pedrosa Nunes
Kenia Pedrosa Nunes
Vascular Smooth Muscle Cells (VSMC) dysfunction is a major contributor to Type 1 diabetes (T1D)-associated vascular complications. Ca2+ is a key messenger responsible for maintaining VSMC tone and function, and alterations in its cytosolic levels are central to diabetes-related vasculopathy. Heat Shock Protein 70 (HSP70), a multifaceted chaperone present intracellularly (iHSP70), regulates vascular reactivity by supporting Ca2+ handling, and extracellularly (eHSP70) activates immune signaling. Disruption of eHSP70/iHSP70 balance has been implicated in T1D-associated VSMC dysfunction. Curcumin, a phytochemical found in turmeric, is an emerging therapeutic adjuvant for treating a wide range of pathologies, including diabetes. However, whether curcumin modulates Ca2+ dynamics and HSP70 expression, thereby improving VSMC function, in diabetic aorta remains unclear. To investigate this, Streptozotocin-induced diabetic rats (i.p. 65 mg/kg) were treated with curcumin (300 mg/kg) for 28 days. Vascular function was evaluated using wire myography to assess changes in biphasic contraction curve and Ca2+ dynamics, while HSP70 was quantified using Western blotting and ELISA. Structural alterations were analyzed by assessing collagen and elastin using Picrosirius staining and fluorescence microscopy. Chronic curcumin treatment improved vascular function by normalizing Ca2+ mishandling, restoring the eHSP70/iHSP70 ratio, reducing hypercontractility, and mitigating arterial structural alterations. These findings indicate that curcumin could potentially ameliorate diabetes-related VSMC dysfunction by restoring Ca2+ homeostasis and modulating HSP70.

Verified
Journal Article
Open access
PDF file
SRSwasti Rastogi
Swasti Rastogi
JLJessica Liaw
Jessica Liaw
YZYingnan Zhai
Yingnan Zhai
TKTatiana Karpova Karpova
Tatiana Karpova Karpova
Linxia GuLinxia Gu
Linxia Gu
KNKenia Pedrosa Nunes
Kenia Pedrosa Nunes
Hypertension, a leading factor for cardiovascular diseases (CVD), is a particularly heavy burden in women during middle age, when cardioprotective hormones begin to decline. The abnormal handling of calcium (Ca2+) in vascular smooth muscle cells (VSMCs) leads to increased vasoconstriction, remodeling, and altered arterial compliance during hypertension. The Spontaneously Hypertensive Rats (SHR) is a model of essential hypertension, and middle-aged females with hypertension represent a stage of disease where vascular dysfunction is prominent but understudied. Losartan, a widely prescribed angiotensin II (AngII) receptor (AT1R) blocker, exerts antihypertensive effects by affecting Ang II/Ca2+ signaling. However, whether it corrects the Ca2+ mishandling in the aorta of middle-aged female SHR has not been established. In this study, the thoracic aorta from 36-week-old female SHRs treated with losartan was assessed for Ca2+ mishandling using myography and biochemical assays. Meanwhile, biomechanical properties and stiffness were evaluated using Pulse Wave Velocity (PWV), Atomic Force Microscopy (AFM), and assessments of collagen and elastin contents. Compared with normotensive controls, SHR demonstrated disrupted Ca2+ handling, increased stiffness, and Extracellular Matrix (ECM) remodeling in middle-aged females. Treatment with losartan abrogated Ca2+ mishandling influx and efflux in the VSMC, decreased stiffness, and restored the aortic structural changes. These findings demonstrate that losartan abolishes Ca2+ mishandling and highlight a mechanistic role of AT1R blockade in restoring vascular function in the aorta of middle-aged females during hypertension.

29 June 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
Valentina Ochoa MendozaValentina Ochoa Mendoza
Valentina Ochoa Mendoza
SRSwasti Rastogi
Swasti Rastogi
CWConner ryan Weaver
Conner ryan Weaver
MSMicheline Rosa Silveira
Micheline Rosa Silveira
KNKenia Pedrosa Nunes
Kenia Pedrosa Nunes
Type 2 diabetes (T2D) is a chronic metabolic disorder leading to increased cardiovascular risk and vascular dysfunction. Hyperglycemia, a hallmark of T2D, drives hypercontractility, thereby compromising vascular function. Heat shock protein 70 (HSP70) has emerged as an important player in vascular reactivity under physiological conditions via its interaction with calcium mobilization, and in T2D, blocking this protein prevents hypercontractility. Circulating extracellular HSP70 (eHSP70) has also been proposed as a biomarker in chronic diseases, as it can function as a damage-associated molecular pattern (DAMP) to activate the innate immune system and promote low-grade inflammation. Berberine (BBR), a natural alkaloid with anti-inflammatory properties, has been shown to attenuate vascular contraction by modulating intracellular calcium handling. Yet the link between HSP70 and BBR in modulating vascular contraction in T2D remains unknown. Therefore, we investigated whether acute and/or chronic BBR treatment modulates HSP70 to prevent vascular hypercontractility in the T2D mouse model. For acute ex vivo treatment, db/+ and db/db aortic rings were incubated for 30 min with or without the HSP70 inhibitor VER155008, in the presence or absence of BBR or vehicle. For chronic in vivo treatment, db/+ and db/db mice received intraperitoneal BBR injections (10 mg/kg, 3 times per week) and BBR in their drinking water (0.5 mg/mL) for 28 days. Following chronic (4 weeks, in vivo) or acute ex vivo (30 min) BBR treatment, vascular function was assessed in aortic rings isolated from male T2D (db/db) and age-matched non-diabetic (db/+) mice using wire myography. Rings were incubated with or without the HSP70 inhibitor VER155008, in the presence or absence of BBR or vehicle. Overt hyperglycemia and hypercontractility were observed in diabetic animals compared with non-diabetic controls. While acute BBR treatment attenuated vasoconstriction in both diabetic and nondiabetic groups, the combination of BBR and VER155008 produced a stronger inhibitory effect only in the diabetic group. Chronic BBR treatment prevented aortic hypercontractility in diabetic mice; however, the synergistic effect with VER155008 was no longer observed. Additionally, BBR reduced systemic HSP70 levels. Collectively, these findings indicate that BBR improves vascular smooth muscle cells’ function in T2D, at least in part, through HSP70-dependent mechanisms during chronic treatment.

13 September 2026 in Cells
Verified
Journal Article
Open access
PDF file
SRSwasti Rastogi
Swasti Rastogi
JLJessica Liaw
Jessica Liaw
YLYair Lara-Blanco
Yair Lara-Blanco
Valentina Ochoa MendozaValentina Ochoa Mendoza
Valentina Ochoa Mendoza
KNKenia Pedrosa Nunes
Kenia Pedrosa Nunes
Diabetes and hypertension are closely interlinked and among the most prevalent diseases that significantly increase cardiovascular risks. They can be caused by a wide range of factors, which often affect overlapping molecular pathways, resulting in vascular dysfunction. Hyperglycemia in diabetes and increased angiotensin II levels in hypertension act similarly to promote vascular dysfunction by triggering pathways leading to oxidative stress, low-grade inflammation, and vessel remodeling. In this context, Heat Shock Protein 70 (HSP70), a ubiquitous molecular chaperone that exists locally (iHSP70) and systemically (eHSP70) and has opposing biological effects, is emerging as a new component associated with vascular dysfunction in chronic conditions. While elevated levels of eHSP70 in diabetes and hypertension have been associated with low-grade inflammation, iHSP70 appears to regulate intracellular calcium handling—a hallmark mechanism disrupted in both pathologies. This review focuses on the role of HSP70 as an evolving component of the intricate mechanisms underlying vascular dysfunction in these two pervasive diseases, which are very likely to coexist and represent a growing burden worldwide, while addressing whether HSP70 actively contributes to the vascular dysfunction or reflects an adaptive response to disease-associated stress across tissues and experimental models. Finally, we discuss emerging evidence on the pharmacological modulation of HSP70 and the challenges remaining in defining its role as a biomarker and therapeutic target.